Literature DB >> 30107548

High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis.

Mark Ford1, Ilfita Sahbudin1,2,3, Andrew Filer1,2,3, Neil Steven4,5, Benjamin A Fisher1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30107548     DOI： 10.1093/rheumatology/key234

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  10 in total

Review 1.  Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy.

Authors:  Brendan L Mangan; Renee K McAlister; Justin M Balko; Douglas B Johnson; Javid J Moslehi; Andrew Gibson; Elizabeth J Phillips
Journal:  Br J Clin Pharmacol       Date:  2020-07-17       Impact factor: 4.335

Review 2.  Role of pharmacogenomics in T-cell hypersensitivity drug reactions.

Authors:  Rebecca J Hertzman; Pooja Deshpande; Andrew Gibson; Elizabeth J Phillips
Journal:  Curr Opin Allergy Clin Immunol       Date:  2021-08-01

3.  Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective.

Authors:  Neil M Steven; Benjamin A Fisher
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

Review 4.  The Roles of Immunoregulatory Networks in Severe Drug Hypersensitivity.

Authors:  Yun-Shiuan Olivia Hsu; Kun-Lin Lu; Yun Fu; Chuang-Wei Wang; Chun-Wei Lu; Yu-Fen Lin; Wen-Cheng Chang; Kun-Yun Yeh; Shuen-Iu Hung; Wen-Hung Chung; Chun-Bing Chen
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

Review 5.  Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions.

Authors:  Yueran Li; Pooja Deshpande; Rebecca J Hertzman; Amy M Palubinsky; Andrew Gibson; Elizabeth J Phillips
Journal:  Front Genet       Date:  2021-04-16       Impact factor: 4.599

6.  Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity.

Authors:  Sean Hammond; Anna Olsson-Brown; Sophie Grice; Andrew Gibson; Joshua Gardner; Jose Luis Castrejón-Flores; Carol Jolly; Benjamin Alexis Fisher; Neil Steven; Catherine Betts; Munir Pirmohamed; Xiaoli Meng; Dean John Naisbitt
Journal:  Toxicol Sci       Date:  2022-02-28       Impact factor: 4.849

7.  Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature.

Authors:  Jing-Yi Wu; Kai Kang; Jing Yi; Bin Yang
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

Review 8.  Drug and Chemical Allergy: A Role for a Specific Naive T-Cell Repertoire?

Authors:  Rami Bechara; Alexia Feray; Marc Pallardy
Journal:  Front Immunol       Date:  2021-06-29       Impact factor: 7.561

9.  Does immune checkpoint inhibitor therapy increase the frequency of adverse reactions to concomitant medications?

Authors:  Sean Hammond; Anna Olsson-Brown; Sophie Grice; Dean J Naisbitt
Journal:  Clin Exp Allergy       Date:  2022-03-25       Impact factor: 5.401

10.  T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab.

Authors:  Sean Hammond; Anna Olsson-Brown; Joshua Gardner; Paul Thomson; Serat-E Ali; Carol Jolly; Dan Carr; Lorenzo Ressel; Munir Pirmohamed; Dean Naisbitt
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.